Medfiniti is a medtech platform holding company combining patented non-thermal treatment technology, recurring procedure-based revenue, and scalable infrastructure within a single operating model.
Medfiniti is built on a patented, non-thermal treatment technology platform with clinical, operating, and data applications.
Revenue is tied to procedural utilization and consumable demand rather than one-time capital equipment sales.
The company is developing compliant procedural and patient data capabilities as part of its long-term platform architecture.
Intellectual property, commercialization, and operating deployment are organized within a unified corporate structure.
The model is designed to support expansion without duplicating core infrastructure across each operating layer.
The company is structured to support phased regulatory and commercial expansion across selected international markets.
HemWell MD Gen 2 soft-launched in Q4 2025 and launched fully in February 2026 with enhanced device architecture and improved connectivity. The rollout is underway across 63 active clinical centers nationwide, replacing Gen 1 systems while maintaining continuity of patient care and physician utilization.
Gen 1 launched in 2020. The HemWell MD technology has supported 40,000+ procedures since Medfiniti acquired it: about 20,000 at the original company-owned surgery center and about 20,000 since commercial launch. Gen 2 expands on this foundation with stronger operating infrastructure and enhanced platform capabilities.
Visit HemWell MDMedfiniti separates intellectual property, platform management, and operating deployment within a deliberate corporate structure.
Strategic pathways for disciplined international growth across priority markets.
Current commercial focus with active physician adoption and operating activity.
Government and military channels under evaluation through targeted institutional relationships.
Planned regional structure supporting future regulatory and commercial entry.
Planned expansion into selected Gulf and North African markets through regional partnerships.
Choose the most relevant way to engage with the company.